AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04225676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients > 50 kg body weight.
Study NCT00951236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: One cortisone injection
Description: Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
Study NCT00951236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two cortisone Injections
Description: Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
Study NCT00760942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Similac special care 30
Description: Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
Study NCT00760942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Similac human milk fortifier
Description: Powdered human milk fortifier.
Study NCT02422836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three Product Anti-Aging Treatment Regimen
Description: Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
Study NCT02213185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMLA patches
Description: EMLA patches 1.5 hrs before sterile water injections
Study NCT02213185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMLA patches
Description: EMLA patches 1.5 hrs before sterile water injections
Study NCT02213185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EMLA patches
Description: EMLA patches 1.5 hrs before sterile water injections
Study NCT03487588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Topical Solution
Description: A-101 Topical Solution applied Day 1, Day 15 and Day 29
Study NCT02823054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZ-Blocker
Description: the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
Study NCT03645421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 100 μg
Description: Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
Study NCT03645421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 200 μg
Description: Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
Study NCT03645421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 300 μg
Description: Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
Study NCT03645421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PlaceboA
Description: 1.0 mL liquid formulation per Vial
Study NCT03645421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 50 ug
Description: Solution for injection, 1.0 mL per vial, 50 ug
Study NCT03645421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PlaceboB
Description: Solution for injection in 1.0 mL pre-filled syringe.
Study NCT02379221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable
Description: 20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
Study NCT02379221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical
Description: 4% Topicaine gel
Study NCT01739686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CASA Intervention
Description: CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone.
Study NCT03048890 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical activity levels
Description: Patients with severely low physical activity levels will be notified to consult their physician.
Study NCT01610557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections).
Study NCT01610557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections).
Study NCT02839187 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neuroimaging
Description: AV45-positron emission tomography
Study NCT02839187 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Description: AV45-positron emission tomography
Study NCT03079908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: da Vinci Skills Simulator®
Description: Initial robotic virtual reality surgical simulator Training (da Vinci Skills Simulator ® System), then laparoscopic dry box evaluation
Study NCT03079908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LapSim®
Description: Initial laparoscopic virtual reality surgical simulator training (LapSim ® System), then laparoscopic dry box evaluation
Study NCT03079908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dry lab box laparoscopic training
Description: No initial simulator training. Dry lab box laparoscopic Training only.
Study NCT01255657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-806
Description: ABT-806 will be administered by intravenous infusion.
Study NCT02308085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrine therapy interruption
Description: 3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.~Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference.
Study NCT03789513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV test with partial genotyping and VIA triage
Description: HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
Study NCT00194584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 week Building on Family Strengths Program
Description: Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
Study NCT00303771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT00303771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00303771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00303771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study NCT01656785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BNOTA-PRGD2
Description: Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
Study NCT02269345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture
Description: Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
Study NCT02269345 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment
Description: Standard Treatment alone.
Study NCT04193657 — intervention group
Intervention type: OTHER
Intervention: Daily and weekly triggered symptom monitoring
Description: Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.
Study NCT03145350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-fat, low-carbohydrate
Description: Dietary intervention: 4 week
Study NCT03145350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat, high-carbohydrate
Description: Dietary intervention: 4 week
Study NCT00662363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 µg po BID given with meals for 6 days
Study NCT00662363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna
Description: 2 tabs daily for 6 days
Study NCT00303771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT05071989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education
Description: A single-blind school- based randomized controlled design
Study NCT03273374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Description: IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
Study NCT01092754 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: contrast enhanced MRI
Study NCT01092754 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gadoversetamide
Description: Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
Study NCT04521075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation by capsules
Description: Cohorts A and B - Patients will receive 30 oral capsules per administration for two consecutive days (Days 1-2) Cohort C - Patients will receive FMT via colonscopy (Day 1), followed the day after by adnistration of 12 oral capsules (Day 2)~Combination cycles: 6 combined cycles Q2W of FMT maintenance followed by treatment with anti-PD1. Anti-PD-1 will be administered at least one day and up to 3 days after the FMT.~Maintenance of FMT by oral capsules: 12 capsules per administration. Anti PD-1 therapy: A dose of 240 mg Nivolumab will be administrated by intravenous infusion.
Study NCT01306591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab 1
Description: Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
Study NCT01306591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
Study NCT01548521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
Study NCT02127879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: 16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
Study NCT02127879 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation with sham coil
Description: 16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
Study NCT01627522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Description: Transurthral resection of prostate
Study NCT01535053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study NCT04276870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Murine CART19
Description: CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection with a planned dose of 5x106 CART19 cells/kg on day 0 with possible reinfusion/retreatment
Study NCT03076021 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isotretinoin
Description: Drug interaction study
Study NCT03076021 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dextromethorphan
Description: Drug interaction study
Study NCT01549886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-90-Zevalin
Description: Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
Study NCT01549886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Y-90-Zevalin
Description: Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
Study NCT01549886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxtezafin Gadolinium
Description: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m\^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily
Study NCT01549886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Day 1 and Day 8: Rituximab 250 mg/m\^2 intravenous infusion
Study NCT01549886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Day 1 and Day 8: Rituximab 250 mg/m\^2 intravenous infusion
Study NCT04675658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBPA + family support
Description: Classroom Based Physical Activity + family support as described in the Arm
Study NCT04675658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBPA
Description: Classroom Based Physical Activity
Study NCT04696367 — intervention group
Intervention type: PROCEDURE
Intervention: Emergency laparotomy
Description: Midline laparotomy for acute intra-abdominal pathology
Study NCT01679548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port LAVH
Description: LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.
Study NCT01679548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-port LAVH
Description: Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
Study NCT02974855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 subcutaneous (SC) injection
Study NCT02974855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 SC injection
Study NCT03120260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Intervention 'Diet+ short sleep versus normal sleep
Study NCT00129701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telephone consultation
Study NCT02750345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg Tablet will be administered.
Study NCT02750345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone Baked Tablet
Description: A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
Study NCT03739658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Cognitive-Based Neuromuscular Training has the content of focusing on different tasks at the same time and coordinating on neuromuscular functions as well as football-specific movements. Game-Based Training (OTE), which includes football, tennis, bowling, shooting, racing and climbing games, consists of active video games of game consoles, which are frequently used among young people.
Study NCT03104517 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control is the vehicle solution used for the study product.
Study NCT01535053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO
Study NCT01535053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV and IM
Study NCT01535053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01535053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00179634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visualization relaxation
Study NCT00179634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Milieu Enhancement (Fine art photograph)
Study NCT02893878 — intervention group
Intervention type: OTHER
Intervention: Vaccine safety surveillance
Description: Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
Study NCT01892228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate post-screening treatment education
Description: immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
Study NCT01386554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection
Description: Acthar given SC for 6 months
Study NCT01386554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week).
Study NCT02499302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental training
Study NCT03542981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Current
Study NCT03542981 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Interferential Current
Study NCT04541940 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Therapy
Description: Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
Study NCT04541940 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person Rehabilitation Therapy
Description: Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
Study NCT01463540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A 20 Fr gastrostomy tube, placed using push/pull techniques.
Description: In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.